Drug intelligence / Profile preview

BSC2101

Development stage: Preclinical
Lead developer: BiSiChem
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

BSC2101 is a preclinical-stage STING (Stimulator of Interferon Genes) agonist developed by BiSiChem. It is specifically designed to serve as a payload for antibody-drug conjugates (ADCs) targeting solid cancers. The mechanism involves the activation of the STING pathway, which triggers the production of Type I interferons and other pro-inflammatory cytokines. This innate immune activation is intended to turn 'cold' tumors 'hot' by recruiting and activating T cells within the tumor microenvironment, thereby enhancing the overall anti-tumor immune response.

Targets

STING (Stimulator of interferon genes protein)

Beyond the preview

Go deeper on BSC2101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BSC2101.

Explore the full profile